Rachna Shroff, MD, MS, FASCO, discusses the potential role for nab-paclitaxel plus gemcitabine and cisplatin in select patients with biliary tract cancers.
Back
SWOG S1815: Exploring the Limits and Lessons of Triplet Chemotherapy in Biliary Tract Cancer
Rachna T. Shroff, MD, MS, FASCO, discusses lessons learned from the phase 3 SWOG S1815 trial evaluating triplet chemotherapy in newly diagnosed, advanced biliary tract cancer.
SWOG S1815: Exploring the Limits and Lessons of Triplet Chemotherapy in Biliary Tract Cancer
Episodes
All
All
Rachna Shroff, MD, MS, FASCO, discusses the efficacy of nab-paclitaxel plus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancer.
Dr Shroff discusses the SWOG S1815 trial of nab-paclitaxel plus gemcitabine and cisplatin in patients with newly diagnosed, advanced biliary tract cancer.
Results from SWOG S1815 showed no survival benefit for nab-paclitaxel plus gemcitabine and cisplatin in advanced biliary tract cancer.
Advertisement
Advertisement
Trending on OncLive
1
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
2
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
3
Mo-Rez Advances Into Combination Studies Following Robust Responses in Gynecologic Cancers
4
mRNA Vaccines May Help Increase Long-Term Disease Control in PDAC
5